Vericel (VCEL) Income from Continuing Operations (2010 - 2026)
Vericel (VCEL) posted Income from Continuing Operations of 1763000.0 for Q2 2026, up 125.78% sequentially from 6838000.0 in Q1 2026, and up 276.83% YoY from 467849.61 in Q2 2025.
Powered by 
Analysis
Vericel (VCEL) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Vericel has reported Income from Continuing Operations for 17 years, with the latest figure at 1763000.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 276.83% year-over-year to 1763000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 22826000.0 (up 271.21% YoY) and the FY2025 annual result came in at 16518000.0, up 59.41% from the prior year.
- Income from Continuing Operations climbed to 1763000.0 in Q2 2026 per VCEL's latest filing, from 6838000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 23268000.0 in Q4 2025 and troughed at 164411000.0 in Q2 2023.
- A 5-year average of 8902666.67 and a median of 3993500.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slumped 1734.33% in 2023, then jumped 614.21% in 2025.
- Over 5 years, Income from Continuing Operations stood at 5922000.0 in 2022, then surged by 119.4% to 12993000.0 in 2023, then soared by 52.44% to 19807000.0 in 2024, then rose by 17.47% to 23268000.0 in 2025, then sank by 92.42% to 1763000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1763000.0, 6838000.0, and 23268000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.88 Bn | 56.40 Mn | 2.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.23 Mn |
| Mar 31, 2026 | -6.37 Mn |
| Dec 31, 2025 | 24.14 Mn |
| Sep 30, 2025 | 5.10 Mn |
| Jun 30, 2025 | -529,000.00 |
| Mar 31, 2025 | -11.29 Mn |
| Dec 31, 2024 | 19.81 Mn |
| Sep 30, 2024 | -901,000.00 |
| Jun 30, 2024 | -4.67 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | 12.99 Mn |
| Sep 30, 2023 | -3.66 Mn |
| Jun 30, 2023 | -5.02 Mn |
| Mar 31, 2023 | -7.48 Mn |
| Dec 31, 2022 | 5.92 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -8.96 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | -4.93 Mn |